Navigation Links
Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting
Date:9/3/2009

EMERYVILLE, Calif., Sept. 3 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that new research data will be delivered as an oral presentation during the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA on September 13, 2009. The presentation will describe results from a multi-institutional collaborative in vitro study of Adamas' triple combination antiviral drug (TCAD) therapy.

    Presentation details:

    Title:            Triple Combination of Amantadine, Ribavirin and
                      Oseltamivir Restores In Vitro Activity of Antiviral
                      Drugs against Resistant Influenza Viruses

    Date/Time:        Sunday, Sep 13, 2009, 10:45 AM -11:00 AM

    Session:          064-Respiratory Viruses and Influenza
                      Sunday, Sep 13, 2009, 8:30 AM -11:00 AM

    Abstract Number:  V-537b

    Location:         Marriott Salon 9

    Authors:          J. T. NGUYEN (1), J. HOOPES (2), D. SMEE (2),
                      M. LE (1), A. PATICK (1), M. DE JONG (3),
                      G. WENT (1), D. FAIX (4), P. BLAIR (4),
                      M. PRICHARD (5);
                      (1) Adamas Pharmaceuticals, Emeryville, CA,
                      (2) Utah State Univ., Logan, UT,
                      (3) Amsterdam Med. Ctr., Amsterdam, Netherlands,
                      (4) Naval Health Research Center, San Diego, CA,
                      (5) Univ. of Alabama, Birmingham, AL.

About TCAD

Adamas is pioneering triple-combination antiviral drug (TCAD) therapy for influenza, which is designed to inhibit viral replication at multiple points during the virus life cycle. TCAD therapy includes Adamas' investigational proprietary fixed-dose combination of amantadine and ribavirin, to be administered adjunct
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2015)... According to a new market research ... & Non-Portable), Component (Accelerometer, Proximity Probe, & Others), ... Mining, & Others), & Geography - Global Forecast ... reach $1,453.76 Million by 2020, at a CAGR ... and 92 figures spread through 205 pages and ...
(Date:4/29/2015)... GUELPH, ON , April 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... twelve-month periods ended December 31, 2014. Biorem,s complete fiscal 2014 year-end financial ... FINANCIAL HIGHLIGHTS: 2014 , 2013 , 2014 ... 10,683 , 19,596 Gross profit 1,326 , ... 1,191 , 1,493 , 3,377 , ...
(Date:4/29/2015)... EAST RUTHERFORD, N.J. , April 29, 2015 ... 2015 financial results will be released on Friday, May 1, ... The Company will host a conference ... Conference Call When: , Friday, ... Dial-in: , 1-888-468-2440 for U.S.1-719-325-2454 for International ...
(Date:4/29/2015)... (PRWEB) April 29, 2015 The leading ... announce that its regenerative stem cell therapy has processed ... 2002, seeking to discover a successful treatment for horses ... In 2003 VetStem signed a worldwide exclusive license for ... and the first horse was treated in January 2004. ...
Breaking Biology Technology:Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2
... applications for the real world, has formalized ... Inc. One of the many businesses that ... Tier 1 automotive supplier focusing on technology-rich ... and Lumidigm will bring patented biometric functionality ...
... N.J., Aug. 5 Ortho Biotech is announcing,that it is voluntarily ... cracks in the necks of a,small number of vials upon post-manufacturing ... Approximately 44,292 vials of lot,P114942A in the following packaging configurations were ... NDC ...
... Replidyne, Inc.,(Nasdaq: RDYN ) today announced its financial ... 2008., Replidyne reported a net loss of $18.7 million ... per basic and diluted common share of $0.69,per share, compared ... share or $1.65 per common share on a fully diluted ...
Cached Biology Technology: Lumidigm Signs Strategic Agreement with Methode Electronics : Automotive Supplier Invests in Biometric Component Development 2Ortho Biotech Announces Nationwide Voluntary Recall of Procrit(R) (Epoetin Alfa) Lot Number P114942A 2Replidyne Announces Second Quarter 2008 Results From Operations 2Replidyne Announces Second Quarter 2008 Results From Operations 3Replidyne Announces Second Quarter 2008 Results From Operations 4Replidyne Announces Second Quarter 2008 Results From Operations 5Replidyne Announces Second Quarter 2008 Results From Operations 6Replidyne Announces Second Quarter 2008 Results From Operations 7
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... American Pregnancy Association, six million women a year deal with ... hope to women who want to conceive ― in the ... shelves right now. Prof. Adrian Shulman of Tel Aviv ... has found a statistical connection between the over-the-counter vitamin supplement ...
... at the Living Planet Symposium have been hearing about ... almost three months, the satellite is in excellent health ... presented at the symposium. Prof. Duncan Wingham, Lead ... in very good shape exceeding in-orbit specifications, the ...
... study of the occurrence of fishes in the ocean,s deepest ... species of fishes are more numerous at such depths than ... published in the July/August issue of BioScience , observed ... meters around a baited video lander in the Japan Trench. ...
Cached Biology News:Increasing fertility threefold 2CryoSat-2 exceeding expectations 2Study suggests more fish than thought may thrive in the ocean's depths 2
...
Use as the souce of CETP enzyme for screening CETP inhibitors. Use in conjunction with the CETP activity assay kit (K601-100)....
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
Biology Products: